Skip to main content
PMC home page
Nucleic Acids Research logoLink to Nucleic Acids Research
. 1998 Sep 15;26(18):4128–4136. doi: 10.1093/nar/26.18.4128

The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element.

J A Brown 1, E M Rogers 1, J M Boss 1
PMCID: PMC147839  PMID: 9722631

Abstract

The class II transactivator CIITA is required for transcriptional activation of the major histocompatibility complex (MHC) class II genes. Aside from an N-terminal acidic transcriptional activation domain, little is known about how this factor functions. Extensive mutagenesis of CIITA was undertaken to identify structural motifs required for function. The ability of mutants to activate a reporter gene under the control of MHC class II conserved W-X-Y or X-Y regulatory elements was determined. Two mutants displayed differential activity between the two promoters, activating transcription with the W-X-Y but not the X-Y elements. All mutants were tested for their ability to interfere with wild-type CIITA activity. Five CIITA mutant constructions were able to down-regulate wild-type CIITA activity. Three of these mutants contained targeted disruptions of potential functional motifs: the acidic activation domain, a putative GTP-binding motif and two leucine charged domains (LCD motifs). The other two contained mutations in regions that do not have homology to described proteins. The characterization of CIITA mutants that are able to discriminate between promoters with or without the W box strongly suggests that CIITA requires such interactions for function. The identification of LCD motifs required for CIITA function brings to light a previously undefined role of these motifs in CIITA function.

Full Text

The Full Text of this article is available as a PDF (481.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Accolla R. S. Human B cell variants immunoselected against a single Ia antigen subset have lost expression of several Ia antigen subsets. J Exp Med. 1983 Mar 1;157(3):1053–1058. doi: 10.1084/jem.157.3.1053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aperlo C., Pognonec P., Stanley E. R., Boulukos K. E. Constitutive c-ets2 expression in M1D+ myeloblast leukemic cells induces their differentiation to macrophages. Mol Cell Biol. 1996 Dec;16(12):6851–6858. doi: 10.1128/mcb.16.12.6851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Attardi L. D., Von Seggern D., Tjian R. Ectopic expression of wild-type or a dominant-negative mutant of transcription factor NTF-1 disrupts normal Drosophila development. Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10563–10567. doi: 10.1073/pnas.90.22.10563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Basta P. V., Sherman P. A., Ting J. P. Detailed delineation of an interferon-gamma-responsive element important in human HLA-DRA gene expression in a glioblastoma multiform line. Proc Natl Acad Sci U S A. 1988 Nov;85(22):8618–8622. doi: 10.1073/pnas.85.22.8618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Basta P. V., Sherman P. A., Ting J. P. Identification of an interferon-gamma response region 5' of the human histocompatibility leukocyte antigen DR alpha chain gene which is active in human glioblastoma multiforme lines. J Immunol. 1987 Feb 15;138(4):1275–1280. [PubMed] [Google Scholar]
  6. Benoist C., Mathis D. Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. Annu Rev Immunol. 1990;8:681–715. doi: 10.1146/annurev.iy.08.040190.003341. [DOI] [PubMed] [Google Scholar]
  7. Bontron S., Steimle V., Ucla C., Eibl M. M., Mach B. Two novel mutations in the MHC class II transactivator CIITA in a second patient from MHC class II deficiency complementation group A. Hum Genet. 1997 Apr;99(4):541–546. doi: 10.1007/s004390050403. [DOI] [PubMed] [Google Scholar]
  8. Bontron S., Ucla C., Mach B., Steimle V. Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy. Mol Cell Biol. 1997 Aug;17(8):4249–4258. doi: 10.1128/mcb.17.8.4249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Boss J. M. Regulation of transcription of MHC class II genes. Curr Opin Immunol. 1997 Feb;9(1):107–113. doi: 10.1016/s0952-7915(97)80166-5. [DOI] [PubMed] [Google Scholar]
  10. Boss J. M., Strominger J. L. Regulation of a transfected human class II major histocompatibility complex gene in human fibroblasts. Proc Natl Acad Sci U S A. 1986 Dec;83(23):9139–9143. doi: 10.1073/pnas.83.23.9139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Brown J. A., He X. F., Westerheide S. D., Boss J. M. Characterization of the expressed CIITA allele in the class II MHC transcriptional mutant RJ2.2.5. Immunogenetics. 1996;43(1-2):88–91. doi: 10.1007/BF00186611. [DOI] [PubMed] [Google Scholar]
  12. Bénichou B., Strominger J. L. Class II-antigen-negative patient and mutant B-cell lines represent at least three, and probably four, distinct genetic defects defined by complementation analysis. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4285–4288. doi: 10.1073/pnas.88.10.4285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Chakrabartty A., Doig A. J., Baldwin R. L. Helix capping propensities in peptides parallel those in proteins. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11332–11336. doi: 10.1073/pnas.90.23.11332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Chang C. H., Fodor W. L., Flavell R. A. Reactivation of a major histocompatibility complex class II gene in mouse plasmacytoma cells and mouse T cells. J Exp Med. 1992 Nov 1;176(5):1465–1469. doi: 10.1084/jem.176.5.1465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Chang C. H., Fontes J. D., Peterlin M., Flavell R. A. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J Exp Med. 1994 Oct 1;180(4):1367–1374. doi: 10.1084/jem.180.4.1367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Chin K. C., Li G. G., Ting J. P. Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: generation of transdominant-negative mutants. Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2501–2506. doi: 10.1073/pnas.94.6.2501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Chin K. C., Li G., Ting J. P. Activation and transdominant suppression of MHC class II and HLA-DMB promoters by a series of C-terminal class II transactivator deletion mutants. J Immunol. 1997 Sep 15;159(6):2789–2794. [PubMed] [Google Scholar]
  18. Chin K. C., Mao C., Skinner C., Riley J. L., Wright K. L., Moreno C. S., Stark G. R., Boss J. M., Ting J. P. Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction. Immunity. 1994 Nov;1(8):687–697. doi: 10.1016/1074-7613(94)90039-6. [DOI] [PubMed] [Google Scholar]
  19. Clauss I. M., Gravallese E. M., Darling J. M., Shapiro F., Glimcher M. J., Glimcher L. H. In situ hybridization studies suggest a role for the basic region-leucine zipper protein hXBP-1 in exocrine gland and skeletal development during mouse embryogenesis. Dev Dyn. 1993 Jun;197(2):146–156. doi: 10.1002/aja.1001970207. [DOI] [PubMed] [Google Scholar]
  20. Cogswell J. P., Austin J., Ting J. P. The W element is a positive regulator of HLA-DRA transcription in various DR+ cell types. J Immunol. 1991 Feb 15;146(4):1361–1367. [PubMed] [Google Scholar]
  21. Dever T. E., Glynias M. J., Merrick W. C. GTP-binding domain: three consensus sequence elements with distinct spacing. Proc Natl Acad Sci U S A. 1987 Apr;84(7):1814–1818. doi: 10.1073/pnas.84.7.1814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Durand B., Sperisen P., Emery P., Barras E., Zufferey M., Mach B., Reith W. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J. 1997 Mar 3;16(5):1045–1055. doi: 10.1093/emboj/16.5.1045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Epstein M. A., Achong B. G., Barr Y. M., Zajac B., Henle G., Henle W. Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J Natl Cancer Inst. 1966 Oct;37(4):547–559. [PubMed] [Google Scholar]
  24. Fontes J. D., Jiang B., Peterlin B. M. The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32. Nucleic Acids Res. 1997 Jun 15;25(12):2522–2528. doi: 10.1093/nar/25.12.2522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Glimcher L. H., Kara C. J. Sequences and factors: a guide to MHC class-II transcription. Annu Rev Immunol. 1992;10:13–49. doi: 10.1146/annurev.iy.10.040192.000305. [DOI] [PubMed] [Google Scholar]
  26. Griscelli C., Lisowska-Grospierre B., Mach B. Combined immunodeficiency with defective expression in MHC class II genes. Immunodefic Rev. 1989;1(2):135–153. [PubMed] [Google Scholar]
  27. Hasegawa S. L., Boss J. M. Two B cell factors bind the HLA-DRA X box region and recognize different subsets of HLA class II promoters. Nucleic Acids Res. 1991 Nov 25;19(22):6269–6276. doi: 10.1093/nar/19.22.6269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Hasegawa S. L., Riley J. L., Sloan J. H., 3rd, Boss J. M. Protease treatment of nuclear extracts distinguishes between class II MHC X1 box DNA-binding proteins in wild-type and class II-deficient B cells. J Immunol. 1993 Mar 1;150(5):1781–1793. [PubMed] [Google Scholar]
  29. Heery D. M., Kalkhoven E., Hoare S., Parker M. G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997 Jun 12;387(6634):733–736. doi: 10.1038/42750. [DOI] [PubMed] [Google Scholar]
  30. Herrero Sanchez C., Reith W., Silacci P., Mach B. The DNA-binding defect observed in major histocompatibility complex class II regulatory mutants concerns only one member of a family of complexes binding to the X boxes of class II promoters. Mol Cell Biol. 1992 Sep;12(9):4076–4083. doi: 10.1128/mcb.12.9.4076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hooft van Huijsduijnen R., Li X. Y., Black D., Matthes H., Benoist C., Mathis D. Co-evolution from yeast to mouse: cDNA cloning of the two NF-Y (CP-1/CBF) subunits. EMBO J. 1990 Oct;9(10):3119–3127. doi: 10.1002/j.1460-2075.1990.tb07509.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Jabrane-Ferrat N., Fontes J. D., Boss J. M., Peterlin B. M. Complex architecture of major histocompatibility complex class II promoters: reiterated motifs and conserved protein-protein interactions. Mol Cell Biol. 1996 Sep;16(9):4683–4690. doi: 10.1128/mcb.16.9.4683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Kara C. J., Glimcher L. H. Developmental and cytokine-mediated regulation of MHC class II gene promoter occupancy in vivo. J Immunol. 1993 Jun 1;150(11):4934–4942. [PubMed] [Google Scholar]
  34. Kjeldgaard M., Nyborg J., Clark B. F. The GTP binding motif: variations on a theme. FASEB J. 1996 Oct;10(12):1347–1368. [PubMed] [Google Scholar]
  35. Louis-Plence P., Moreno C. S., Boss J. M. Formation of a regulatory factor X/X2 box-binding protein/nuclear factor-Y multiprotein complex on the conserved regulatory regions of HLA class II genes. J Immunol. 1997 Oct 15;159(8):3899–3909. [PubMed] [Google Scholar]
  36. Louis-Plence P., Moreno C. S., Boss J. M. Formation of a regulatory factor X/X2 box-binding protein/nuclear factor-Y multiprotein complex on the conserved regulatory regions of HLA class II genes. J Immunol. 1997 Oct 15;159(8):3899–3909. [PubMed] [Google Scholar]
  37. Mach B., Steimle V., Reith W. MHC class II-deficient combined immunodeficiency: a disease of gene regulation. Immunol Rev. 1994 Apr;138:207–221. doi: 10.1111/j.1600-065x.1994.tb00853.x. [DOI] [PubMed] [Google Scholar]
  38. Mahanta S. K., Scholl T., Yang F. C., Strominger J. L. Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6324–6329. doi: 10.1073/pnas.94.12.6324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Moreno C. S., Emery P., West J. E., Durand B., Reith W., Mach B., Boss J. M. Purified X2 binding protein (X2BP) cooperatively binds the class II MHC X box region in the presence of purified RFX, the X box factor deficient in the bare lymphocyte syndrome. J Immunol. 1995 Nov 1;155(9):4313–4321. [PubMed] [Google Scholar]
  40. Moreno C. S., Rogers E. M., Brown J. A., Boss J. M. Regulatory factor X, a bare lymphocyte syndrome transcription factor, is a multimeric phosphoprotein complex. J Immunol. 1997 Jun 15;158(12):5841–5848. [PubMed] [Google Scholar]
  41. Pober J. S., Collins T., Gimbrone M. A., Jr, Cotran R. S., Gitlin J. D., Fiers W., Clayberger C., Krensky A. M., Burakoff S. J., Reiss C. S. Lymphocytes recognize human vascular endothelial and dermal fibroblast Ia antigens induced by recombinant immune interferon. Nature. 1983 Oct 20;305(5936):726–729. doi: 10.1038/305726a0. [DOI] [PubMed] [Google Scholar]
  42. Reith W., Kobr M., Emery P., Durand B., Siegrist C. A., Mach B. Cooperative binding between factors RFX and X2bp to the X and X2 boxes of MHC class II promoters. J Biol Chem. 1994 Aug 5;269(31):20020–20025. [PubMed] [Google Scholar]
  43. Reith W., Satola S., Sanchez C. H., Amaldi I., Lisowska-Grospierre B., Griscelli C., Hadam M. R., Mach B. Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein, RF-X. Cell. 1988 Jun 17;53(6):897–906. doi: 10.1016/s0092-8674(88)90389-3. [DOI] [PubMed] [Google Scholar]
  44. Reith W., Siegrist C. A., Durand B., Barras E., Mach B. Function of major histocompatibility complex class II promoters requires cooperative binding between factors RFX and NF-Y. Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):554–558. doi: 10.1073/pnas.91.2.554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Riley J. L., Boss J. M. Class II MHC transcriptional mutants are defective in higher order complex formation. J Immunol. 1993 Dec 15;151(12):6942–6953. [PubMed] [Google Scholar]
  46. Riley J. L., Westerheide S. D., Price J. A., Brown J. A., Boss J. M. Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA). Immunity. 1995 May;2(5):533–543. doi: 10.1016/1074-7613(95)90033-0. [DOI] [PubMed] [Google Scholar]
  47. Scholl T., Mahanta S. K., Strominger J. L. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6330–6334. doi: 10.1073/pnas.94.12.6330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Seidl C., Saraiya C., Osterweil Z., Fu Y. P., Lee J. S. Genetic complexity of regulatory mutants defective for HLA class II gene expression. J Immunol. 1992 Mar 1;148(5):1576–1584. [PubMed] [Google Scholar]
  49. Shaulian E., Zauberman A., Ginsberg D., Oren M. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol. 1992 Dec;12(12):5581–5592. doi: 10.1128/mcb.12.12.5581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Silacci P., Mottet A., Steimle V., Reith W., Mach B. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J Exp Med. 1994 Oct 1;180(4):1329–1336. doi: 10.1084/jem.180.4.1329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Sims T. N., Elliott J. F., Ramassar V., Denney D. W., Jr, Halloran P. F. Mouse class II transactivator: cDNA sequence and amino acid comparison with the human class II transactivator. Immunogenetics. 1997;45(3):220–222. doi: 10.1007/s002510050193. [DOI] [PubMed] [Google Scholar]
  52. Sloan J. H., Boss J. M. Conserved upstream sequences of human class II major histocompatibility genes enhance expression of class II genes in wild-type but not mutant B-cell lines. Proc Natl Acad Sci U S A. 1988 Nov;85(21):8186–8190. doi: 10.1073/pnas.85.21.8186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Sloan J. H., Hasegawa S. L., Boss J. M. Single base pair substitutions within the HLA-DRA gene promoter separate the functions of the X1 and X2 boxes. J Immunol. 1992 Apr 15;148(8):2591–2599. [PubMed] [Google Scholar]
  54. Steimle V., Durand B., Barras E., Zufferey M., Hadam M. R., Mach B., Reith W. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev. 1995 May 1;9(9):1021–1032. doi: 10.1101/gad.9.9.1021. [DOI] [PubMed] [Google Scholar]
  55. Steimle V., Otten L. A., Zufferey M., Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell. 1993 Oct 8;75(1):135–146. [PubMed] [Google Scholar]
  56. Steimle V., Siegrist C. A., Mottet A., Lisowska-Grospierre B., Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science. 1994 Jul 1;265(5168):106–109. doi: 10.1126/science.8016643. [DOI] [PubMed] [Google Scholar]
  57. Stimac E., Urieli-Shoval S., Kempin S., Pious D. Defective HLA DRA X box binding in the class II transactive transcription factor mutant 6.1.6 and in cell lines from class II immunodeficient patients. J Immunol. 1991 Jun 15;146(12):4398–4405. [PubMed] [Google Scholar]
  58. Torchia J., Rose D. W., Inostroza J., Kamei Y., Westin S., Glass C. K., Rosenfeld M. G. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature. 1997 Jun 12;387(6634):677–684. doi: 10.1038/42652. [DOI] [PubMed] [Google Scholar]
  59. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Trzepacz C., Lowy A. M., Kordich J. J., Groden J. Phosphorylation of the tumor suppressor adenomatous polyposis coli (APC) by the cyclin-dependent kinase p34. J Biol Chem. 1997 Aug 29;272(35):21681–21684. doi: 10.1074/jbc.272.35.21681. [DOI] [PubMed] [Google Scholar]
  61. Tsang S. Y., Nakanishi M., Peterlin B. M. B-cell-specific and interferon-gamma-inducible regulation of the HLA-DR alpha gene. Proc Natl Acad Sci U S A. 1988 Nov;85(22):8598–8602. doi: 10.1073/pnas.85.22.8598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Unanue E. R., Harding C. V., Luescher I. F., Roof R. W. Antigen-binding function of class II MHC molecules. Cold Spring Harb Symp Quant Biol. 1989;54(Pt 1):383–392. doi: 10.1101/sqb.1989.054.01.047. [DOI] [PubMed] [Google Scholar]
  63. Walker J. E., Saraste M., Runswick M. J., Gay N. J. Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J. 1982;1(8):945–951. doi: 10.1002/j.1460-2075.1982.tb01276.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Westerheide S. D., Louis-Plence P., Ping D., He X. F., Boss J. M. HLA-DMA and HLA-DMB gene expression functions through the conserved S-X-Y region. J Immunol. 1997 May 15;158(10):4812–4821. [PubMed] [Google Scholar]
  65. Wright K. L., Ting J. P. In vivo footprint analysis of the HLA-DRA gene promoter: cell-specific interaction at the octamer site and up-regulation of X box binding by interferon gamma. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7601–7605. doi: 10.1073/pnas.89.16.7601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Yun S., Gustafsson K., Fabre J. W. Suppression of MHC class II expression by human class II trans-activator constructs lacking the N-terminal domain. Int Immunol. 1997 Oct;9(10):1545–1553. doi: 10.1093/intimm/9.10.1545. [DOI] [PubMed] [Google Scholar]
  67. Zhou H., Glimcher L. H. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency. Immunity. 1995 May;2(5):545–553. doi: 10.1016/1074-7613(95)90034-9. [DOI] [PubMed] [Google Scholar]
  68. Zhou H., Su H. S., Zhang X., Douhan J., 3rd, Glimcher L. H. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant. J Immunol. 1997 May 15;158(10):4741–4749. [PubMed] [Google Scholar]
  69. de Préval C., Lisowska-Grospierre B., Loche M., Griscelli C., Mach B. A trans-acting class II regulatory gene unlinked to the MHC controls expression of HLA class II genes. Nature. 1985 Nov 21;318(6043):291–293. doi: 10.1038/318291a0. [DOI] [PubMed] [Google Scholar]

Articles from Nucleic Acids Research are provided here courtesy of Oxford University Press

RESOURCES